Cytokinetics (CYTK) EBT Margin (2016 - 2024)
Historic EBT Margin for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to 1655.61%.
- Cytokinetics' EBT Margin rose 97047700.0% to 1655.61% in Q4 2024 from the same period last year, while for Dec 2024 it was 7765.51%, marking a year-over-year increase of 147311300.0%. This contributed to the annual value of 1522.37% for FY2024, which is 84879900.0% up from last year.
- Latest data reveals that Cytokinetics reported EBT Margin of 1655.61% as of Q4 2024, which was up 97047700.0% from 32338.88% recorded in Q3 2024.
- In the past 5 years, Cytokinetics' EBT Margin ranged from a high of 1655.61% in Q4 2024 and a low of 57391.16% during Q2 2024
- In the last 5 years, Cytokinetics' EBT Margin had a median value of 2459.95% in 2021 and averaged 9414.31%.
- Over the last 5 years, Cytokinetics' EBT Margin had its largest YoY gain of 97047700bps in 2024, and its largest YoY loss of -425014300bps in 2024.
- Quarter analysis of 5 years shows Cytokinetics' EBT Margin stood at 320.68% in 2020, then crashed by -120bps to 64.69% in 2021, then plummeted by -10492bps to 6851.66% in 2022, then dropped by -17bps to 8049.16% in 2023, then skyrocketed by 121bps to 1655.61% in 2024.
- Its last three reported values are 1655.61% in Q4 2024, 32338.88% for Q3 2024, and 57391.16% during Q2 2024.